A phase 1/2 trial (NCT05706129) is currently assessing [177Lu]Lu-DPI-4452, a peptide ligand targeting CAIX [56], in patients with ccRCC as well as pancreatic adenocarcinoma and colorectal cancer. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.